Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ezetimibe/obicetrapib - NewAmsterdam Pharma

Next Previous
Drug Profile

Ezetimibe/obicetrapib - NewAmsterdam Pharma

Alternative Names: AMG-899/ezetimibe - NewAmsterdam Pharma; DEZ-001/ezetimibe - NewAmsterdam Pharma; Evlarco; obicetrapib/ezetimibe - NewAmsterdam Pharma; TA-8995/ezetimibe - NewAmsterdam Pharma

Latest Information Update: 07 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NewAmsterdam Pharma
  • Developer Menarini; NewAmsterdam Pharma
  • Class Amines; Antidementias; Antihyperlipidaemics; Azetidines; Butyric acids; Carbamates; Esters; Ethers; Fluorobenzenes; Fluorocarbons; Phenols; Propanols; Pyrimidines; Quinolines; Small molecules; Trihalomethanes
  • Mechanism of Action Cholesterol absorption inhibitors; Cholesterol ester transfer protein inhibitors; NPC1L1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Dyslipidaemias; Hypercholesterolaemia
  • Phase III Coronary artery disease

Most Recent Events

  • 23 Jul 2026 Preregistration for Dyslipidaemias (Combination therapy) in European Union (PO)
  • 23 Jul 2026 Preregistration for Dyslipidaemias (Monotherapy) in European Union (PO)
  • 23 Jul 2026 Preregistration for Hypercholesterolaemia (Combination therapy) in European Union (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top